No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human IGFBP2 Antibodies:
anti-Mouse (Murine) IGFBP2 Antibodies:
anti-Rat (Rattus) IGFBP2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal IGFBP2 Primary Antibody for IHC, ELISA - ABIN966350
Stewart, Weigel: Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. in The Prostate 2005
Show all 3 Pubmed References
Human Monoclonal IGFBP2 Primary Antibody for IHC, ELISA - ABIN1724698
Miyake, Hara, Yamanaka, Muramaki, Gleave, Eto: Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. in Oncology reports 2005
Show all 2 Pubmed References
Human Monoclonal IGFBP2 Primary Antibody for IHC (fro), IHC (p) - ABIN449962
Berger, Hsieh, Bakele, Marcos, Rieber, Kormann, Mays, Hofer, Neth, Vitkov, Krautgartner, von Schweinitz, Kappler, Hector, Weber, Hartl: Neutrophils express distinct RNA receptors in a non-canonical way. in The Journal of biological chemistry 2012
High IGFBP2 expression is associated with chemoresistance of lung cancer.
IGFBP-2 plasma levels outperformed the established risk score for prediction of one-year mortality in aortic stenosis patients undergoing transcatheter aortic valve implantation.
High IGFBP2 expression is associated with salivary adenoid cystic carcinoma metastasis.
Low IGFBP2 expression is associated with obesity.
Findings suggest that the long non-coding RNA HOTAIR (HOTAIR) - insulin growth factor-binding protein 2 (IGFBP2)axis plays critical roles in renal cell carcinoma (RCC) metastasis and may serve as a therapeutic target for advanced RCC.
IGFBP2 acts as a stimulator of Vasculogenic mimicry formation in glioma cells via enhancing CD144 and MMP2 expression.
Downregulation of IGFBP2 expression is specific for bipolar disorder.
IGFBP2 protects EAC cells against ABS-induced DNA damage and apoptosis through stabilization and activation of EGFR - DNA-PKcs signaling axis.
Study showed that IGFBP2 was highly expressed in clinical tissues of melanoma compared with the control group, and its expression exhibited a positive association with CD147. furthermore, IGFBP2 participated in CD147-mediated apoptosis in melanoma.
Serum IGFBP-2 levels increase with age after the age of 50 years and evolve in parallel with insulin sensitivity. IGFBP-2 may therefore be a potential marker for insulin sensitivity. We further show that IGFBP-2 levels can predict mortality in this aging population. However, its predictive value for mortality can only be interpreted in relation to insulin sensitivity.
Following IGFBP2 knockdown using rAAV2-ZsGreen-shRNA-hIGFBP2, matrix metalloproteinase2 expression was significantly reduced in tumor tissues compared with that in rAAV2ZsGreenshRNAscramble treated tumor tissues.
IGFBP2 overexpression increased the expression of p-p65 and nuclear p65, while IGFBP2 knockdown reduced the expression of p-p65 and nuclear p65.
The associated effects appear to be mediated by inhibition of IGFBP-2 expression and stimulation of p21 expression. This suggests that simulated microgravity might represent a promising method to discover new targets for glioma therapeutic strategy.
these results suggest that IGFBP2 plays an important role in promoting tumorigenesis, through estrogen and ERalpha signaling pathway.
patients with low IGFBP2 expressiondisplay a clear advantage in overall and disease-free survival, whereas those with high IGFBP2 expressionhave worse median survival than IDH-wildtype patients.
The interaction of IGFBP2 and p63 might account for the pathogenesis of rhabdomyosarcoma tumors.
Co-ordinated and reciprocal alteration in IGFBP-2 and -5 expression may play a role in the acquisition of endocrine resistance in breast cancer.
We verified that NFIA binds to the IGFBP2 promoter and transcriptionally enhances IGFBP2 expression levels. We identified that NFIA-mediated IGFBP2 signaling pathways are involved in miR-302b-induced glioma cell death.
Insulin-like growth factor binding protein 2 potentiates glioblastoma tumor growth by the activation of the beta-catenin pathway through its C-terminal domain, and their coexpression possibly contributes to worse patient prognosis.
mechanistic investigations defined insulin-like growth factor binding protein 2 (IGFBP2)as a direct and functional downstream target of microRNA-592, which was involved in the microRNA-592-mediated tumor-suppressive effects in glioma cells.
AAV6-mediated IGFBP-2 overexpression in the tibialis anterior (TA) muscles of 4-week-old C57BL/10 and mdx mice reduced the mass of injected muscle after 8weeks, inducing a slower muscle phenotype in C57BL/10 but not mdx mice. Analysis of inflammatory and fibrotic gene expression revealed no changes between control and IGFBP-2 injected muscles in dystrophic (mdx) mice.
Peptides that disrupted p62/PKCzeta or p62/IRS-1 inhibited IGF-I/IGFBP-2 stimulated PKCzeta activation, vimentin phosphorylation, PTEN tyrosine phosphorylation, AKT activation, and osteoblast differentiation.
In human whole blood cells, methylation of IGFBP2 at the homologous CpG site was increased in obese men with impaired glucose tolerance. In conclusion, our data show that increased methylation of hepatic Igfbp2 during infancy predicts the development of fatty liver later in life and is linked to deterioration of glucose metabolism.
IGFBP2 not only is a driver of glioma progression and a prognostic factor but is also required for tumour maintenance and thus represents a viable therapeutic target in the treatment of glioma.
that the lacking the Arg-Gly-Asp-domain has a major influence on the pleiotropic effects of IGFBP-2 and suggest that somatic growth and time of sexual maturity or somatic growth and life expectancy are less closely related than thought previously
Data (including data from studies in knockout mice) suggest, as osteoblasts differentiate, early induction of AMPK in response to IGF-I/IGFBP-2 is followed by suppression of AMPK as required for osteogenesis; activation of AMPK stimulates autophagy.
estrogen deficiency has a profound effect on body and bone composition in the absence of IGFBP-2 and may be related to changes in fibroblast growth factor 21.
Impaired glucose clearance in female IGFBP-2 transgenic mice is dependent on the presence of the RGD motif and that translocation of GLUT4 in the muscle may be regulated by IGFBP-2 via RGD-dependent mechanisms.
protein(s) that associated with RPTPbeta in response to IGF-I and IGFBP-2 in vascular smooth muscle cells
The results suggest that stimulation of differentiation is an important mechanism by which IGFBP-2 regulates the acquisition of normal bone mass in mice.
PPARalpha controls IGF-1 signalling through the up-regulation of hepatic Igfbp-2 transcription during fasting.
IGFBP2 is a critical cell-autonomous factor that promotes the survival and migration of acute leukemia cells.
IGFBP-2 plays an IGF-I-dependent and -independent role in the brain's acute (neuroprotection) and chronic (tissue remodeling) response to hypoxic-ischemic injury.
physiological levels of IGFBP2 are neither sufficient to mimic nor required for the physiological action of leptin
Igfbp2-5 are expressed in distinct and complementary patterns during cochlear development.
These findings demonstrate that the HBD2 domain of IGFBP-2 is the primary region that accounts for its ability to inhibit adipogenesis and that a peptide encompassing this region has activity that is comparable with native IGFBP-2.
we have identified a single polymorphic locus that affects skin and lung tumorigenesis and identify Igfbp5 and Igfbp2 as candidate modifier genes of lung tumorigenesis.
IGFBP-2 bound receptor protein tyrosine phosphatase beta, which led to its dimerization and inactivation. Analysis of aortas obtained from IGFBP-2(-/-) mice showed that receptor protein tyrosine phosphatase beta was activated.
findings suggest that insulin upregulates IGFBP-2 expression through a PI3K/mTOR/C/EBP-alpha pathway in white adipocytes
Data from transgenic mice suggest that hepatic leptin signaling (i.e., direct action of leptin on hepatocytes) is not required for leptin up-regulation of plasma levels of IGFBP-2; intact vagus nerve is also not required.
Results suggest that IGFBP-2 is associated with production performance in pigs.
IGFBP-2 is required for general embryonic development and growth and plays a local role in regulating vascular development in a model vertebrate organism.
The igfbp2(30-32kDa)is similarities to mammalian size.
The identification and characterization of two IGFBP-2 genes in zebrafish and four other teleost fish, is reported.
Five novel SNPs were identified in IGFBP2, two of which had significant associations with fertility (age at conception in heifers and commencement of luteal activity) and 305-day milk yield in lactation 1.
The present study suggests that the insulin like growth factor (IGF) system or imbalances between IGF and IGF binding proteins may be involved in cystic ovary disease of cattle.
in preovulatory follicles, PAPP-A is responsible for IGF-dependent IGFBP-2 degradation
spatial and temporal patterns of expression of IGFBP-2 and -3 were markedly altered in the placentomes of nuclear transfer pregnancies
protein that binds to Igf-I and Igf-II
, IGF-binding protein 2
, insulin-like growth factor-binding protein 2
, insulin-like growth factor binding protein 2b
, insulin-like growth factor binding protein 2
, IGF binding protein 2
, insulin-like growth factor binding protein 2, 36kDa
, insulin-like growth factor-binding protein-2, IGFBP-2
, IGF-binding protein 2-B
, insulin-like growth factor binding protein 2a
, insulin-like growth factor-binding protein 2-B
, insulin-like growth factor binding protein-II